DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 1 Piper Sandler - 1 Kraft Heinz - 1 Ronald Epstein - 1 Epstein - 1 — Alex Harring - 1 Oppenheimer - 1 Rupesh Parikh - 1
Top related locs:
Tuesday's Swiss Shopify
Top related orgs:
CNBC - 1 Garmin Garmin - 1 Bank of America - 1 Garmin - 1 Costco - 1 Citi - 1 Kraft - 1 ~$ - 1

Search resuls for: "Daniel Grosslight"


3 mentions found


☆ Wednesday's analyst calls: Goldman says e-commerce stock will rally 30%, food giant gets upgraded
  + stars: | 2024-05-22 | by ( Alex Harring Fred Imbert | Alex Harring | Fred Imbert | ) www.cnbc.com   time to read: +9 min
Analyst Ronald Epstein downgraded the electronics maker to underperform from neutral and slashed $15 off his price target to $150. Analyst Rupesh Parikh reiterated his outperform rating on the wholesaler, while lifting his price target by $45 to $850. Analyst Tal Liani reiterated his buy rating on the software stock and price target of $315. Analyst Gabriela Borges upgraded the retail software stock to buy from neutral and raised her price target by $7 to $74. He also slapped a $42 price target on the stock, implying upside of nearly 17%.
Persons: Goldman Sachs, Piper Sandler, Kraft Heinz, Ronald Epstein, Epstein, — Alex Harring, Oppenheimer, Rupesh Parikh, Parikh, Alex Harring, Daniel Grosslight, Grosslight, HIMS, he's, Tal Liani, Liani, CORA, it's, Morgan Stanley, Josh Baer, Baer, Box's, there's, Goldman, Gabriela Borges, Borges, Shopify, Michael Lavery, Lavery, KHC, Fred Imbert Organizations: CNBC, Garmin Garmin, Bank of America, Garmin, Costco, Citi, Kraft, ~$ Locations: Tuesday's, Swiss, Shopify
☆ Inside digital health's reckoning, where once-hot startups are suddenly scrambling for cash
  + stars: | 2023-01-31 | by ( Blake Dodge | Rebecca Torrence | ) www.businessinsider.com   time to read: +11 min
Analysts and CEOs told Insider more than half of healthcare startups will shut down by 2024. Healthcare startups looking to stay afloat have been laying off employees left and right. The online pharmacy Truepill burned through its cash as it struggled to fill prescriptions efficiently, two former employees told Insider. A spokesperson for Truepill told Insider in an email that the company's burn rate was in line with its projections. Courtesy NOCDWhile the broader economic pressures will hurt many startups that can't raise, it may help others, experts told Insider.
☆ GoodRx is a buy that can surge 60% from here, Citi says
  + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
The sell-off in telemedicine name GoodRx is overdone, and now is a good time to buy the stock, according to Citi. "In our view, GDRX will continue to serve a vital role in bringing transparency/consumerism to a historically unshopable market," Grosslight wrote in a Wednesday note. In addition to its focus on generic retail prescription drugs, GoodRx has recently expanded into branded Rx spending as well. the recently announced ESI partnership for commercial members)," Grosslight wrote. "In our view, the market has been too punitive, effectively pricing in no terminal value," he added.
0 next >>
Total: 3